



Facile synthesis of salmochelin S1, S2, MGE, DGE, and TGE

Xiaolong Yu^{a,†}, Yijing Dai^{a,†}, Tao Yang^a, Michel R. Gagné^b, Hegui Gong^{a,*}

^aShanghai University, Department of Chemistry, Shanghai 200444, China

^bUniversity of North Carolina at Chapel Hill, Department of Chemistry, Chapel Hill, NC 27599, USA

ARTICLE INFO

Article history:

Received 10 August 2010

Received in revised form 31 October 2010

Accepted 2 November 2010

Available online 5 November 2010

Keywords:

Salmochelin

Total synthesis

Aryl β-C-glucoside

ABSTRACT

Salmochelin S1, S2, MGE, DGE, and TGE were prepared through amide bond connection of an aryl C-glucosyl acyl chloride (Ar¹COCl) and serine ester amines, followed by hydrogenolysis of the per-benzylated precursors. Each synthesis employed a highly diastereoselective Ni-catalyzed Negishi approach to the aryl C-glycoside subunit.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Iron is crucial for most bacteria to grow. In mammalian cells, the iron concentration is very low ($\sim 10^{-24}$ M) due to the low solubility of iron under physiological conditions and the presence of strong Fe³⁺-binding proteins.¹ To secure their iron supply, bacteria have evolved to produce small molecular siderophores to bind and transport iron from the environment.^{1–6} For instance, Enterobactin (Ent), a 2,3-dihydroxybenzoyl (DHB) serine macrotrilactone (Chart 1) with a K_d for Fe³⁺ of $\sim 10^{-49}$ M is one of the most studied siderophores.² The mono and di-C-glucosylated Ent derivatives (Chart 1), termed salmochelins, are produced from *Salmonella* species, uropathogenic, and avian pathogenic *Escherichia coli* strains, and certain *Klebsiella* strains.³ Studies indicated that salmochelins are better Fe³⁺ siderophores than Ent in the presence of serum albumin and played a more important role for pathogenic processes in certain *E. Coli* and *Salmonella* infections.^{3,4} Intensive exploration of the mechanism of how bacteria use glucosylated Ent as virulence factors has been carried out by Hantke,³ Walsh and Liu⁵ and others.⁶ The enzyme-mediated in vitro syntheses of salmochelin S1, S2, SX, and the mono- (MGE), di- (DGE or salmochelin S4), and tri-C-glucosylated Ent (TGE) derivatives (Chart 1) have been achieved.^{5b–d,6a}

An efficient chemical synthesis of the salmochelins would provide complementary access to these naturally-occurring compounds and allow for systematic structural deviations that would further bio-studies.^{5,7} Our recent success in the development of

a Ni-catalyzed Negishi approach to alkyl and aryl C-glycosides (e.g., Scheme 1)⁸ has opened up opportunities to stereoselectively prepare relevant bio-active natural products containing C-glycoside cores that may otherwise be difficult to obtain using classical methods.^{9,10} Using this method as the key step, the total synthesis of salmochelin SX, the structurally simplest derivative in the salmochelin family, has been achieved.^{8a} The significance of the salmochelins as siderophores in nature prompted us to carry out and present herein a full account on the syntheses of the structurally more complex salmochelin S1, S2, and S4 (DGE) and the TGE and MGE derivatives (Chart 1).

2. Results and discussion

The structures of the salmochelins and the analogs possess characteristic amide bond connection arising from the corresponding L-serine ester amines (Chart 1) with C-glucosylated DHB and DHB (Chart 2). Whereas DGE, TGE, and MGE employed a cyclic tri-L-serine lactone amine, salmochelin S1 and S2 consist of linear di- and tri-L-serine ester amines, respectively (Chart 1). Hence, our general synthetic strategy for the salmochelins focused on an amide bond forming fragment assembly of a per-benzylated glucosyl acyl chloride **1** (Ar¹COCl)^{8a} and benzyl-protected L-serine ester amines, capped by a one-step global hydrogenolysis/deprotection (Scheme 2).

In analogy to the synthesis of Ent,¹¹ the C₃-symmetric TGE was readily obtained by treatment of the trilactone triamine hydrochloride salt **2**^{11a} (Chart 2) with **1**^{8a}, which was prepared based on a modification of our previous procedures.¹² The resulting per-benzylated TGE precursor **3** was obtained in 70% yield. Removal of the benzyl groups furnished TGE in good yield (Scheme 3).

* Corresponding author. Tel.: +86 21 6613 2410; fax: +86 21 6613 4594; e-mail address: hegui.gong@shu.edu.cn (H. Gong).

[†] The first two authors contributed equally to this study.





Chart 1. The structures of salmochelin derivatives.



Scheme 1. Ni-catalyzed Ar- β -C-glucoside formation.^{8a}






Chart 2. Structures of **2**, DHB, C-glucosylated DHB, Ar²CO, and Ar¹CO.




Scheme 2. A retrosynthetic scheme of salmochelin synthesis.



Scheme 3. TGE synthesis. Reaction conditions: (a) **2** (100 mol %), **1** (300 mol %), Et₃N (600 mol %), DCM (0.03 M), 0 °C, 30 min then 22 °C, 5 h, 70% over two steps. (b) H₂, Pd(OH)₂, MeOH/EtOAc 1:1 (0.09 M), 18 h, 92%.

The synthesis of DGE (salmochelin S4) and MGE, however requires installation of both DHB and the C-glucosylated DHB to the trilactone ring **2**. Initial efforts were focused on the incorporation of mono- or di-2,3-bis(benzyloxy)benzoyl (i.e., Ar²CO, see Chart 2) into **2** and **4** with the remaining amine groups being protected (Scheme 4). Nevertheless, this strategy was unsatisfactory; the best results obtained were <18% yields for the preparation of **5** and **6** (Scheme 4). The main reason for these low yields is likely due to the instability of the trilactone ring. It was observed that **2**, **5**, and tri-Boc-protected **2** decomposed in the presence of Et₃N.




Scheme 4. mono- or di-protection of cyclic triamine.

Given the success that per-benzylated TGE **3** and per-benzylated Ent **7** were synthesized by amidation of **2** with Ar¹COCl and Ar²COCl,¹¹ respectively, we reasoned that per-benzylated DGE **8** and per-benzylated MGE **9** could be prepared through amide bond formation from a mixture of the two acid chlorides and **2**. Indeed, conversion of mixtures of Ar¹COOH and Ar²COOH to the acyl chlorides followed by treatment with **2** in the presence of Et₃N, provided mixtures of per-benzylated precursors **3**, **7**, **8**, and **9** (Table 1). The distribution of the products was dependent on the ratio of acids examined. A 1:1 mixture of the two acids appeared to result in optimal overall yields for **8** and **9** with trace of **3** and **7** (entry 1). Hydrogenolysis of **8** and **9** provided DGE and MGE in 92% and 90% yields, respectively.

Salmochelin S1 was prepared from esterification of *N*-Ar²CO-ser(OH)-OBn **10** with *N*-Boc-ser(OBn)-OH **11** (Scheme 5) to form Boc-protected diester **12**. Deprotection with dry HCl¹³ followed by amide bond formation upon treatment with **1** (Ar¹COCl) provided per-benzylated salmochelin S1, which was converted to salmochelin S1 in high yield by hydrogenolysis (Scheme 5).


Table 1
Optimization for the formation of **8** and **9**



Entry ^a	Ar ¹ COOH: Ar ² COOH	3	8	9	7
1	1:1	Trace	27% ^b	42%	Trace
2	2:1	16%	24%	8%	Trace
3	1:2	Trace	7%	38%	14%


^a Reaction conditions: (a) Ar¹COOH+Ar²COOH (300 mol %), SOCl₂, DMF (cat.), DCM (0.2 M). (b) **2** (100 mol %), Et₃N (600 mol %), DCM (0.07 M), 20 °C, 3 h.

^b Yields were calculated over two steps.




Scheme 5. Preparation of salmochelin S1. (a) **11**, EDC/HCl (130 mol %), HOBT (200 mol %), pyridine (230 mol %), CH₃CN (0.1 M), 12 h, 85%. (b) (i) HCl, MeOH/THF. (ii) Et₃N, **1**, DCM, 53%. (c) H₂, Pd(OH)₂, MeOH/EtOAc, 1:1, 90%.

Likewise, preparation of salmochelin S2 was first proposed beginning with coupling of **14** and **11** (Scheme 6). The resulting Boc-protected ester **15** was submitted to hydrogenolysis giving **16** in high yield. Coupling of **16** with **10**, however provided **17** in low yield, along with **12** and an aminoacrylate byproduct. This is due to E2 elimination in the acid activation step.^{14a} It should be noted that *N*-benzoyl serine may undergo racemization under the EDC/HOBT coupling conditions, particularly when the carboxylic acid is not protected.¹⁴ To our delight, no racemization occurred when **10** was utilized. Installation of Ar¹CO to **17** after removal of Boc produced trace amount of per-benzylated salmochelin S2 **18** presumably due to an rapid O→N acyl shift upon neutralization of the linear amine salt (Scheme 6).^{15,16} Variation of temperature and concentration were not successful.¹⁷



Scheme 6. Attempt to preparation of salmochelin S2. Reaction conditions: (a) EDC/HCl (130 mol %), HOBT (180 mol %), *N*-Methylmorpholine (210 mol %), 48 h, 76%. (b) H₂, Pd/C, 21 h, 70%. (c) EDC/HCl (130 mol %), HOBT (180 mol %), *N*-Methylmorpholine (210 mol %), 24 h, 48%. (d) (i) HCl, MeOH/THF. (ii) Et₃N, **1**, DCM.

To circumvent the undesired side reactions (vide infra), a second approach to salmochelin S2 was carefully devised involving the installation of the first Ar¹CO– to a diseryl ester prior to esterification (Scheme 7). Coupling of the THP-protected serine **19**^{14a} and **10** provided the diseryl ester **20**. Removal of THP and Boc followed by amidation with Ar¹COOH gave the diseryl alcohol **21**, which was treated with **11** to produce the triseryl ester **22**. Subsequent deprotection of Boc and acylation with **1** offered **18** in 54% yield. Finally, hydrogenolysis furnished salmochelin S2 in good yield (Scheme 7).



Scheme 7. Reaction conditions: (a) DHP, TsOH/pyridine. (b) H₂, Pd/C, 99% over two steps. (c) **10**, EDC/HCl, HOBT, Pyridine, CH₃CN, 24 h, 83%. (d) HCl, MeOH/THF. (e) Ar¹-COOH, EDC/HCl, HOBT, pyridine, CH₃CN, 24 h, 60% over two steps. (f) **11**, EDC/HCl, HOBT, pyridine, CH₃CN, 24 h, 43%. (g) HCl. (h) EDC/HCl, Et₃N, DCM, 54% over two steps. (i) H₂, Pd(OH)₂, MeOH/EtOAc, 1:1, 90%.

3. Conclusion

In summary, a general and facile synthesis of salmochelin S1, S2, and S4 (DGE), MGE, and TGE was accomplished for the first time. An amide bond forming strategy by coupling of the glucosyl acid chloride with the corresponding amines, and subsequent one-step global deprotection furnished the salmochelins. Finally, the chemical synthesis of salmochelins opens up doors to structurally modified derivatives, which may ultimately become useful for biological studies.

4. Experimental section

4.1. General

For general experimental details see the [Supplementary data](#).

4.2. General procedure a for acylation of amines with 1

To a solution of C-glucosyl acid Ar¹COOH (100 mol %) in dry DCM (0.05 M) were added DMF (cat.) and SOCl₂ (400 mol %). The reaction was stirred for 3 h at 20 °C. After the solvent and excess SOCl₂ were removed under reduce pressure, the acyl chloride **1** was redissolved in DCM. At 0 °C, the resulting solution was added to a solution of amine, which was prepared from a suspension of amine salt (100 mol %) in DCM upon addition of freshly distilled Et₃N (150 mol %). The reaction mixture was allowed to warm to 20 °C, and stirred for 0.5–5 h, at which point it was concentrated over silica gel. Flash column chromatography (SiO₂) gave the amide.

4.3. General procedure B for global Bn-deprotection

To a flame-dried round bottom flask equipped with a magnetic stir bar was loaded a per-benzylated salmocheline precursor, followed by the addition of MeOH/EtOAc (v/v 1:1) and Pd(OH)₂ (20% weight on carbon, wet). The reaction mixture was first purged with argon for 3 min, and then hydrogen for 3 min. After the reaction mixture was stirred for 18 h under hydrogen atmosphere, it was filtered (over Celite) and washed with dry MeOH. The organic solution was collected, and the solvent was removed under reduced pressure to give a white solid.

4.4. General procedure C for removing Boc group

To a solution of Boc-protected serine (0.128 mmol) in anhydrous THF (3.7 mL) at 20 °C was added a solution of anhydrous HCl in MeOH (~1 M, 2.3 mL), which was freshly prepared by the addition of acetyl chloride to MeOH. The reaction mixture was stirred till the starting

material was consumed, which was monitored by TLC, at which point the solvent and excess HCl were removed and dried in vacuo.

4.5. General conditions for preparative RP-HPLC

A solution of a crude salmochelin product in MeOH was filtered through a 0.2 μm (PTFE) Millipore syringe filter (Fisherbrand) before purification by preparative RP-HPLC using a gradient of CH_3CN in 0.1% TFA/ H_2O over 40–45 min, monitored at 220 nm. The solvent was removed on a lyophilizer.

4.6. Procedures and spectral data

4.6.1. (S)-Benzyl 2-(2,3-bis(benzyloxy)benzamido)-3-hydroxypropanoate (10). To an oven-dried round bottom flask charged with H-Ser-OBzl·HCl (1.150 g, 100 mol %, 4.98 mmol), Ar^2COOH (2.000 g, 120 mol %, 5.980 mmol), and EDC·HCl (1.050 g, 110 mol %, 5.480 mmol) were added DCM (25 mL) followed by Et_3N (0.83 mL, 120 mol %, 5.98 mmol). The reaction mixture was stirred at 20 °C overnight. After removal of the solvent, the residue was dissolved in EtOAc (50 mL). The solution was washed with brine, and the organic phase was collected and dried over MgSO_4 . Flash column chromatography (SiO_2 : 20% ethyl acetate in hexanes) gave the product as a white solid (1.75 g, 3.34 mmol, 67% yield). $[\alpha]_D^{24} +57.11$ (c 6.00, DCM). ^1H NMR (500 MHz, CDCl_3): δ 8.90 (d, $J=7.0$ Hz, 1H), 7.10 (dd, $J=2.0$, 7.5 Hz, 1H), 7.48–7.15 (m, 17H), 5.21–5.18 (m, 3H), 5.14 (s, 2H), 5.07 (d, $J=10.5$ Hz, 1H), 4.79 (quint, $J=3.5$ Hz, 1H), 3.88 (q, $J=11.5$ Hz, 2H), 2.68 (s, 1H). ^{13}C NMR (125 MHz, CDCl_3): δ 170.2, 165.7, 151.8, 147.1, 136.4, 136.3, 135.4, 129.2, 128.7, 128.6, 128.5, 128.4, 128.3, 127.9, 126.7, 124.4, 123.3, 117.5, 76.3, 71.4, 67.3, 63.3, 55.5. HRMS (MALDI): m/z $[\text{M}+\text{Na}]^+$ found 534.1888, calcd 534.1893 for $\text{C}_{31}\text{H}_{29}\text{NO}_6\text{Na}$.

4.6.2. (S)-Benzyl 3-((S)-3-(benzyloxy)-2-(tert-butoxycarbonylamino)propanoyloxy)-2-(2,3-bis(benzyloxy)benzamido)propanoate (12). To a solution of **10** (0.500 g, 100 mol %, 0.940 mmol), **11** (0.310 g, 110 mol %, 1.040 mmol), and HOBT (0.250 g, 195 mol %, 1.830 mmol) in dry acetonitrile was added EDC·HCl (0.230 g, 126 mol %, 1.180 mmol) at 0 °C. The mixture was stirred for 1 h at 0 °C, then 1 h at 20 °C. Pyridine (0.175 mL, 230 mol %, 2.160 mmol) was added, and the mixture was stirred for 48 h. After removal of the solvent in vacuo, the residue was dissolved in EtOAc (20 mL). The solution was washed with brine, and the organic phase was collected and dried over MgSO_4 . Flash column chromatography (SiO_2 : 20% ethyl acetate in hexanes) gave the product as a white foam (0.620 g, 0.799 mmol, 85% yield). $[\alpha]_D^{24} -124.22$ (c 0.90, DCM). ^1H NMR (500 MHz, CDCl_3): δ 8.81 (d, $J=8.0$ Hz, 1H), 7.71 (t, $J=5.0$ Hz, 1H), 7.44–7.12 (m, 20H), 5.24 (d, $J=7.0$ Hz, 1H), 5.22 (s, 2H), 5.16–5.04 (m, 6H), 4.53 (dd, $J=10.1$ and 3.5 Hz, 1H), 4.35 (dd, $J=10.1$ and 3.5 Hz, 1H), 4.25 (q, $J=7.0$ Hz, 2H), 4.09 (d, $J=6.0$ Hz, 1H), 3.31 (dd, $J=9.5$ and 3.0 Hz, 1H), 3.25 (dd, $J=3.0$ and 9.5 Hz, 1H), 1.43 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3): δ 170.2, 169.2, 165.2, 155.3, 151.9, 146.9, 137.5, 136.2, 135.2, 129.4, 128.7, 128.6, 128.5, 128.4, 128.3, 128.0, 127.6, 127.5, 126.6, 124.5, 123.2, 117.1, 79.9, 77.3, 77.1, 76.8, 76.2, 73.0, 71.3, 69.4, 67.7, 65.1, 53.8, 51.7. HRMS (MALDI): m/z $[\text{M}+\text{Na}]^+$ found 811.3206, calcd 811.3207 for $\text{C}_{46}\text{H}_{48}\text{N}_2\text{O}_{10}\text{Na}$.

4.6.3. (S)-Benzyl 3-((S)-3-(benzyloxy)-2-(2,3-bis(benzyloxy)-5-((2S,3R,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzamido)propanoyloxy)-2-(2,3-bis(benzyloxy)benzamido)propanoate (13). According to the general procedures C, deprotection of **12** (0.050 g, 100 mol %, 0.065 mmol) was performed using HCl (1 M in 0.88 mL MeOH) in THF (1 mL). After the solvent and excess HCl were removed, DCM (1.0 mL) and Et_3N (73 μL , 800 mol %, 0.520 mmol) were added. To the resulting solution was added a solution of **1** in DCM (1 mL) at 0 °C, which was prepared according to the general procedures A using Ar^1COOH (0.056 g,

100 mol %, 0.065 mmol) in DCM (1.6 mL), DMF (13 μL), and SOCl_2 (30 μL , 600 mol %, 0.174 mmol). The reaction mixture was allowed to warm to 20 °C, and stir for 0.5 h, at which point it was concentrated over silica gel. Flash column chromatography (SiO_2 : 20% EtOAc in hexanes) gave the title product as a white foam (0.052 g, 0.034 mol, 53% yield). $[\alpha]_D^{24} -197.53$ (c 0.90, DCM). ^1H NMR (500 MHz, CDCl_3): δ 7.91 (d, $J=2.0$ Hz, 1H), 7.75 (dd, $J=6.0$ and 4.0 Hz, 1H), 7.46–6.99 (m, 55H), 5.25 (s, 2H), 5.19–5.12 (m, 5H), 5.04 (q, $J=5.0$ Hz, 2H), 5.03–4.93 (m, 4H), 4.91 (d, $J=12.5$ Hz, 1H), 4.64 (d, $J=1.5$ Hz, 2H), 4.63–4.58 (m, 3H), 4.40 (d, $J=9.5$ Hz, 1H), 4.36 (dd, $J=7.5$ and 3.5 Hz, 1H), 4.27 (d, $J=6.5$ Hz, 1H), 4.10 (s, 2H), 3.86–3.75 (m, 5H), 3.63 (dt, $J=9.5$ and 4.5 Hz, 1H), 3.51 (t, $J=9.0$ Hz, 1H), 3.29 (dd, $J=10.0$ and 3.5 Hz, 1H), 3.23 (dd, $J=9.5$ and 3.0 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3): δ 169.6, 169.3, 165.2, 164.6, 151.7, 152.0, 146.6, 147.1, 138.8, 138.4, 138.2, 137.6, 137.5, 136.2, 136.1, 129.6, 129.5, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 126.6, 126.5, 124.5, 123.2, 122.1, 117.2, 116.2, 86.9, 84.0, 81.2, 79.4, 78.4, 76.2, 76.1, 75.6, 75.1, 74.9, 73.6, 72.7, 71.2, 71.1, 69.3, 69.0, 65.2. HRMS (MALDI): m/z $[\text{M}+\text{Na}]^+$ found 1549.6177, calcd 1549.6188 for $\text{C}_{96}\text{H}_{90}\text{N}_2\text{O}_{16}\text{Na}$.

4.6.4. (S)-3-((S)-2-(2,3-Dihydroxy-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzamido)-3-hydroxypropanoyloxy)-2-(2,3-dihydroxybenzamido)propanoic acid (salmochelin S1). This compound was prepared according to the general procedure C using Per-Bn-S1 **13** (0.025 g, 100 mol %, 0.016 mmol) and Pd(OH)₂ (0.030 g, 20% weight on carbon). After the reaction was complete, the reaction mixture was filtered, and the organic solution was collected. The solvent was removed under reduced pressure to give the title compound as a white solid (0.009 g, 0.0145 mmol, 90%). The crude material was further purified with RP-HPLC using a gradient of 0–35% CH_3CN in 0.1% TFA/ H_2O over 45 min $[\alpha]_D^{24} -131.81$ (c 0.50, MeOH). ^1H NMR (500 MHz, CD_3OD): δ 7.45 (s, 1H), 7.32 (d, $J=8.0$ Hz, 1H), 7.06 (s, 1H), 6.96 (d, $J=7.5$ Hz, 1H), 6.76 (t, $J=8.0$ Hz, 1H), 5.00–4.96 (m, 1H), 4.86 (dd, $J=10.1$ and 3.0 Hz, 1H), 4.78 (dd, $J=4.5$ and 4.0 Hz, 1H), 4.56 (dd, $J=5.0$ and 10.5 Hz, 1H), 4.05 (d, $J=9.0$ Hz, 2H), 3.96 (dd, $J=10.5$ and 3.5 Hz, 1H), 3.88 (d, $J=10.0$ Hz, 1H), 3.73 (dd, $J=12.0$ and 5.0 Hz, 1H), 3.47 (quint, $J=8.5$ Hz, 2H), 3.39 (d, $J=8.0$ Hz, 2H). ^{13}C NMR (125 MHz, CD_3OD): δ 170.1, 169.5, 148.4, 148.0, 145.8, 145.5, 130.0, 118.6, 118.5, 118.2, 118.1, 117.7, 115.4, 114.9, 81.7, 80.6, 78.3, 74.9, 70.4, 64.1, 61.6, 61.4, 61.6, 55.2. HRMS (ESI): m/z $[\text{M}]^-$ found 625.1535, calcd 625.1595 for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_{16}$.

4.6.5. (2S)-Benzyl 2-(2,3-bis(benzyloxy)benzamido)-3-((2S)-2-(tert-butoxycarbonylamino)-3-(tetrahydro-2H-pyran-2-yloxy)propanoyloxy)propanoate (20). To a suspension of **14** (1.000 g, 100 mol %, 3.390 mmol) and DHP (1.23 mL, 400 mol %, 13.560 mmol) in DCM (17 mL) was added pyridine *p*-toluenesulfonate (0.085 g, 10 mol %, 0.340 mmol). The mixture immediately turned homogeneous, which was allowed to stir for 1 h at 20 °C. After evaporation of the solvent under reduced pressure, the residual white solid (1.144 g, 3.017 mmol, 89% yield) was dissolved in MeOH/EtOAc (6 mL, v/v 2:1), and Pd/C (0.250 g, 10% weight on carbon, wet) was added. The mixture was first purged with N_2 for 3 min, and then hydrogen for 3 min. After the reaction mixture was stirred for 12 h under hydrogen, it was filtered and washed with dry EtOAc (3 \times 10 mL). The organic solution was collected, and the solvent was removed under reduced pressure to give **19** as colorless oil (0.864 g, 2.987 mmol, 99% yield), which was used without further purification.

To a solution of **19** (0.864 g, 100 mol %, 2.987 mmol) in dry CH_3CN (17 mL) were added **10** (1.733 g, 110 mol %, 3.286 mmol) and HOBT (0.808 g, 200 mol %, 5.974 mmol) at 0 °C, followed by EDC·HCl (0.859 g, 130 mol %, 4.481 mmol). The resulting mixture was stirred for 1 h at 0 °C, then 1 h at 20 °C. Pyridine (0.675 mL, 250 mol %, 8.364 mmol) was added, and the mixture was stirred for

$J=8.0$ Hz, 1H), 5.10 (t, $J=4.0$ Hz, 1H), 5.00 (dd, $J=5.5$ and 4.0 Hz, 1H), 4.85–4.90 (m, 2H), 4.69 (t, $J=4.0$ Hz, 1H), 4.56 (td, $J=10.5$ and 5.0 Hz, 2H), 4.06 (d, $J=7.0$ Hz, 2H), 3.97 (dd, $J=11.5$ and 4.5 Hz, 1H), 3.88 (dt, $J=13.0$ and 2.0 Hz, 3H), 3.71–3.77 (m, 2H), 3.36–3.51 (m, 8H). ^{13}C NMR (125 MHz, CD_3OD): δ 170.6, 170.1, 169.8, 169.5, 169.2, 168.9, 148.5, 148.1, 145.7, 145.5, 145.4, 130.0, 118.6, 118.4, 118.2, 117.7, 117.2, 115.7, 114.9, 114.3, 81.7, 81.6, 80.6, 80.5, 78.3, 78.3, 74.9, 74.8, 70.4, 70.2, 64.2, 63.6, 61.6, 61.5, 55.1, 52.0, 51.8. HRMS (MALDI): m/z $[\text{M}+\text{Na}]^+$ found 1034.2482, calcd 1034.2502 for $\text{C}_{42}\text{H}_{49}\text{N}_3\text{O}_{26}\text{Na}$.

4.6.10. (*S*)-Benzyl 3-((*S*)-3-(benzyloxy)-2-(*tert*-butoxycarbonylamino)propanoyloxy)-2-(*tert*-butoxycarbonylamino)propanoate (**15**). To a solution of **14** (2.000 g, 100 mol %, 6.780 mmol) in dry acetonitrile (14 mL) was added **11** (2.200 g, 110 mol %, 7.450 mmol) and HOBT (1.870 g, 180 mol %, 12.200 mmol) at 0 °C, followed by EDC·HCl (1.690 g, 130 mol %, 8.810 mmol). The resulting mixture was stirred for 1 h at 0 °C, then 1 h at 20 °C. 4-Methyl morpholine (1.6 mL, 210 mol %, 14.240 mmol) was added, and the mixture was stirred for 48 h, at which point the solvent was removed under reduced pressure. The residue was dissolved in EtOAc (50 mL), and the solution was washed with brine. The organic phase was separated and dried over MgSO_4 . Flash column chromatography (SiO_2 : 15% ethyl acetate in hexanes) provided the title compound as a white solid (2.950 g, 5.153 mmol, 76% yield). $[\alpha]_D^{24}$ –17.93 (c 1.90, DCM). ^1H NMR (500 MHz, CDCl_3): δ 7.40–7.29 (m, 10H), 5.55 (d, $J=8.5$ Hz, 1H), 5.36 (d, $J=7.5$ Hz, 1H), 5.27–5.17 (m, 2H), 4.64–4.58 (m, 2H), 4.58 (s, 1H), 4.49 (t, $J=4.0$ Hz, 2H), 4.37–4.36 (m, 1H), 3.74 (dd, $J=3$ and 9.5 Hz, 1H), 3.60 (dd, $J=2.5$ and 9.5 Hz, 1H), 1.46 (s, 9H), 1.44 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3): δ 170.2, 169.6, 155.4, 155.3, 137.3, 135.2, 128.6, 128.5, 128.4, 128.0, 127.8, 127.6, 80.2, 80.1, 73.26, 69.7, 67.6, 65.1, 54.0, 53.2, 28.3, 28.2.

4.6.11. (6*S*,10*S*)-10-(Benzyloxymethyl)-2,2,14,14-tetramethyl-4,9,12-trioxo-3,8,13-trioxa-5,11-diazapentadecane-6-carboxylic acid (**16**). To a flame-dried round bottom flask (10 mL) equipped with a magnetic stir bar was loaded **15** (1.000 g, 100 mol %, 1.750 mmol), followed by addition of MeOH/EtOAc (3 mL, v/v 2:1) and Pd/C (0.250 g, 10% weight on carbon, wet). The mixture was first purged with argon for 3 min, and then hydrogen for 3 min. After the reaction mixture was stirred for 6 h under hydrogen, it was filtered and washed with dry EtOAc (3×5 mL). The organic solution was collected, and the solvent was removed under reduced pressure to give a white solid (0.807 g, 1.663 mmol, 95% yield). The crude material was used without further purification.

4.6.12. (*S*)-Benzyl 3-((6*S*,10*S*)-10-(benzyloxymethyl)-2,2,14,14-tetramethyl-4,9,12-trioxo-3,8,13-trioxa-5,11-diazapentecanecarbonyloxy)-2-(2,3-bis(benzyloxy)benzamido)propanoate (**17**). To a solution of crude **16** (0.100 g, 110 mol %, 0.208 mmol) in dry acetonitrile (1 mL) were added **10** (0.100 g, 100 mol %, 0.190 mmol) and HOBT (0.050 g, 195 mol %, 0.370 mmol) followed by EDC·HCl (0.046 g, 126 mol %, 0.230 mmol) at 0 °C. The resulting mixture was stirred for 1 h at 0 °C, then 1 h at 20 °C. Pyridine (35 μL , 230 mol %, 0.440 mmol) was added and the reaction mixture was stirred for 48 h. After removal of the solvent under reduced pressure, the residue was dissolved in EtOAc (5 mL). The solution was washed with brine, and the organic phase was separated and dried over MgSO_4 . Flash column chromatography (SiO_2 : 10% ethyl acetate in hexanes) gave the product as a white solid (0.113 g, 0.091 mmol, 48% yield). $[\alpha]_D^{24}$ +124.58 (c 3.20, DCM). ^1H NMR (500 MHz, CDCl_3): δ 8.85 (d, $J=7.5$ Hz, 1H), 7.72 (dd, $J=7.0$ and 2.5 Hz, 1H), 7.47 (d, $J=6.5$ Hz, 2H), 7.43–7.23 (m, 17H), 7.18–7.14 (m, 2H), 5.45 (d, $J=8.5$ Hz, 1H), 5.31 (d, $J=8.5$ Hz, 1H), 5.23 (s, 2H), 5.19–5.08 (m, 6H), 4.58 (d, $J=12.5$ Hz, 1H), 4.50–4.37 (m, 4H), 4.26–4.20 (m, 2H), 3.84 (d, $J=10.5$ Hz, 1H), 3.65 (dd, $J=9.5$ and 3.5 Hz, 1H), 3.49 (dd, $J=5.0$ and 3.0 Hz, 1H), 1.43 (s, 9H), 1.40 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3):

δ 170.0, 169.2, 169.0, 165.3, 155.3, 155.1, 151.9, 147.0, 146.9, 137.3, 136.3, 136.2, 135.2, 129.2, 128.7, 128.6, 128.5, 128.3, 128.0, 127.9, 127.8, 126.5, 124.5, 123.2, 117.4, 80.1, 80.0, 76.2, 73.2, 71.3, 69.6, 67.7, 65.0, 64.4, 54.0, 53.0, 52.0.

4.6.13. *N,N'*-((3*S*,7*S*,11*S*)-11-(2,3-Bis(benzyloxy)-5-((2*S*,3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzamido)-2,6,10-trioxo-1,5,9-trioxacyclododecane-3,7-diyl)bis(2,3-bis(benzyloxy)benzamide) (**9**, Per-Bn-MGE). To an oven-dried round bottom flask charged with Ar^1COOH (0.116 g, 100 mol %, 0.135 mmol) and Ar^2COOH (0.090 g, 200 mol %, 0.270 mmol) in anhydrous DCM (2.0 mL) were added DMF (0.01 mL) and SOCl_2 (0.80 mL) at 20 °C under nitrogen. The reaction was allowed to stir for 2 h, and was removed under reduced pressure to give a yellow solid. After the solvent and excess SOCl_2 were removed under reduced pressure, the acyl chloride was redissolved in DCM (1 mL). At 0 °C, the acid chloride solution was added to a solution of amine, which was prepared from a suspension of trilactone triamine hydrochloride salt (0.050 g, 100 mol %, 0.135 mmol) in DCM (2.0 mL) upon addition of freshly distilled Et_3N (0.12 mL, 600 mol %, 0.809 mmol). The reaction mixture was allowed to warm to 20 °C, and stirred for 5 h, at which point it was dried over silica gel. Flash column chromatography (SiO_2 : 40% EtOAc in hexanes) gave Per-Bn-MGE **9** as a white solid (0.088 g, 0.051 mmol, 38%). $[\alpha]_D^{24}$ –74.47 (c 0.30, DCM). ^1H NMR (500 MHz, CDCl_3): δ 8.56 (t, $J=8.5$ Hz, 2H), 8.52 (d, $J=7.15$ Hz, 1H), 7.90 (s, 1H), 7.69–7.75 (m, 2H), 7.10–7.50 (m, 53H), 6.96–7.02 (m, 2H), 5.20 (dd, $J=11.0$ and 4.0 Hz, 3H), 5.11 (s, 4H), 5.10 (dd, $J=10.5$ and 3.15 Hz, 3H), 4.85–5.05 (m, 8H), 4.67 (d, $J=11.5$ Hz, 2H), 4.61 (d, $J=12.5$ Hz, 1H), 4.45 (d, $J=10.5$ Hz, 1H), 4.28 (d, $J=9.5$ Hz, 1H), 4.15–4.25 (m, 3H), 4.05–4.15 (m, 3H), 3.75–3.90 (m, 5H), 3.65 (d, $J=9.5$ Hz, 1H), 3.50 (t, $J=9.5$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3): δ 169.2, 165.0, 164.6, 151.7, 151.4, 147.0, 146.5, 138.7, 138.3, 138.1, 137.6, 136.3, 136.2, 136.1, 135.8, 135.6, 129.1, 129.0, 128.76, 128.72, 128.70, 128.54, 128.46, 128.43, 128.29, 128.23, 128.08, 127.82, 127.79, 127.72, 127.63, 126.44, 126.41, 126.02, 124.4, 123.3, 122.3, 117.7, 116.6, 86.7, 83.9, 80.9, 79.4, 78.3, 76.43, 76.39, 76.33, 75.6, 75.2, 74.9, 74.5, 71.3, 71.1, 69.2, 64.3, 64.2, 51.53, 51.51, 51.34. HRMS (MALDI): m/z $[\text{M}+\text{Na}]^+$ found 1754.6558, calcd 1754.6563 for $\text{C}_{106}\text{H}_{97}\text{N}_3\text{O}_{20}\text{Na}$.

4.6.14. (*R,R,S,S,R*)-*N,N'*-((3*S*,7*S*,11*S*)-11-(2,3-Bis(benzyloxy)benzamido)-2,6,10-trioxo-1,5,9-trioxacyclododecane-3,7-diyl)bis(2,3-bis(benzyloxy)-5-((2*S*,3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzamide) (**8**, Per-Bn-DGE). To an oven-dried round bottom flask charged with Ar^1COOH (0.231 g, 200 mol %, 0.270 mmol) and Ar^2COOH (0.045 g, 100 mol %, 0.135 mmol) were added DMF (0.01 mL) and SOCl_2 (0.80 mL) in anhydrous DCM (2.0 mL) at 20 °C under nitrogen. The reaction was allowed to stir for 2 h. The solvent and excess SOCl_2 were removed under reduced pressure to give a yellow solid, which was redissolved in DCM (1 mL). At 0 °C, the acid chloride solution was added to a solution of amine, which was prepared from a suspension of trilactone triamine hydrochloride salt (0.050 g, 100 mol %, 0.135 mmol) in DCM (2.0 mL) upon addition of freshly distilled Et_3N (0.12 mL, 600 mol %, 0.809 mmol). The reaction mixture was allowed to warm to 20 °C, and stirred for and stirred for 5 h, at which point it was dried over silica gel. Flash column chromatography (SiO_2 : 40% EtOAc in hexanes) gave the Per-Bn-DGE **8** as a white solid (0.073 g, 0.032 mmol, 24%). $[\alpha]_D^{24}$ –182.93 (c 1.10, DCM). ^1H NMR (500 MHz, CDCl_3): δ 8.62 (d, $J=7.5$ Hz, 1H), 8.58 (t, $J=7.0$ Hz, 2H), 7.93 (d, $J=1.5$ Hz, 2H), 7.71–7.77 (m, 1H), 7.14–7.52 (m, 70H), 6.98–7.05 (m, 4H), 5.22–5.29 (m, 3H), 5.15 (d, $J=8.5$ Hz, 4H), 5.14 (s, 1H), 4.90–5.10 (m, 13H), 4.70 (d, $J=11.0$ Hz, 4H), 4.63 (dd, $J=12.0$ and 1.0 Hz, 2H), 4.48 (dd, $J=10.5$ Hz, 2H), 4.30 (d, $J=9.5$ Hz, 2H), 4.10–4.28 (m, 6H), 3.77–3.90 (m, 10H), 3.68 (dt, $J=6.75$ and 2.55 Hz, 2H), 3.53 (td, $J=9.3$ and 1.45 Hz, 2H). ^{13}C NMR

(125 MHz, CDCl₃): δ 169.3, 169.2, 169.1, 164.9, 164.5, 151.6, 151.3, 146.9, 146.4, 146.3, 138.6, 138.2, 138.0, 137.5, 136.2, 136.1, 136.0, 135.7, 135.5, 135.4, 129.0, 128.9, 128.7, 128.65, 128.60, 128.59, 128.46, 128.43, 128.36, 128.35, 128.31, 128.17, 128.11, 127.9, 127.7, 127.69, 127.67, 127.59, 127.52, 125.9, 125.8, 124.3, 123.2, 122.1, 117.5, 116.4, 86.6, 83.8, 80.8, 79.2, 78.2, 76.31, 76.28, 76.21, 75.5, 75.0, 74.8, 73.4, 71.2, 69.0, 64.1, 63.9, 51.4, 51.2. HRMS (MALDI): m/z [M+Na]⁺ found 2276.8964, calcd 2276.8969 for C₁₄₀H₁₃₁N₃O₂₅Na.

4.6.15. (*R,R,S,S,R,R,R,S,S,R*)-*N,N',N''*-((3*S*,7*S*,11*S*)-2,6,10-Trioxo-1,5,9-trioxacyclododecane-3,7,11-triyl)tris(2,3-bis(benzyloxy)-5-((2*S*,3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2*H*-pyran-2-yl)benzamide) (**3**, Per-Bn-TGE). To an oven-dried round bottom flask charged with Ar¹COOH (0.070 g, 300 mol %, 0.082 mmol) were added DMF (0.01 mL) and SOCl₂ (0.30 mL) in anhydrous DCM (1.0 mL) at 20 °C under nitrogen. The reaction was allowed to stir for 2 h, and the solvent and excess SOCl₂ was removed under reduced pressure to give a yellow solid, which was redissolved in DCM (1 mL). At 0 °C, the acid chloride solution was added to a solution of amine, which was prepared from a suspension of trilactone triamine hydrochloride salt (0.010 g, 100 mol %, 0.027 mmol) in DCM (1.0 mL) up addition of Et₃N (0.023 mL, 600 mol %, 0.162 mmol). The reaction mixture was allowed to warm to 20 °C, and stirred for 5 h, at which point it was concentrated over silica gel. Flash column chromatography (SiO₂: 40% EtOAc in hexanes) gave the Per-Bn-TGE **3** as a white solid (0.052 g, 0.019 mmol, 70%). [α]_D²⁴ –208.24 (c 0.50, MeOH). ¹H NMR (500 MHz, CDCl₃): δ 8.58 (d, *J*=7.5 Hz, 3H), 7.90 (d, *J*=2.0 Hz, 3H), 7.15–7.45 (m, 87H), 6.96–7.01 (m, 6H), 5.23 (d, *J*=11.0 Hz, 3H), 5.10 (d, *J*=11.0 Hz, 3H), 5.02–5.08 (m, 3H), 4.85–5.01 (m, 15H), 4.66 (d, *J*=11.0 Hz, 6H), 4.60 (d, *J*=12.5 Hz, 3H), 4.45 (d, *J*=10.5 Hz, 3H), 4.27 (d, *J*=9.5 Hz, 3H), 4.20 (dd, *J*=10.5 and 5.0 Hz, 3H), 4.14 (t, *J*=9.5 Hz, 3H), 3.74–3.88 (m, 15H), 3.65 (dt, *J*=9.5 and 3.0 Hz, 3H), 3.50 (t, *J*=9.0 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 169.5, 164.6, 151.4, 146.5, 138.7, 138.3, 138.1, 137.6, 136.2, 135.8, 135.6, 129.1, 128.8, 128.7, 128.6, 128.5, 128.48, 128.45, 128.3, 128.2, 128.1, 127.85, 127.81, 127.7, 127.6, 126.0, 122.3, 116.6, 86.7, 84.0, 81.0, 79.4, 78.3, 76.4, 75.6, 75.2, 74.9, 73.5, 71.1, 69.1, 64.1, 51.3. HRMS (MALDI): m/z [M+Na]⁺ found 2799.1370, calcd 2799.1376 for C₁₇₄H₁₆₅N₃O₃₀Na.

4.6.16. *N,N'*-((3*S*,7*S*,11*S*)-11-(2,3-Dihydroxy-5-((2*S*,3*R*,4*R*,5*S*,6*R*)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)benzamido)-2,6,10-trioxo-1,5,9-trioxacyclododecane-3,7-diyl)bis(2,3-dihydroxybenzamide) (MGE). This compound was prepared according to the general procedure B using Per-Bn-MGE **9** (0.030 g, 0.017 mmol, 100 mol %) and Pd(OH)₂ (0.035 g, 20% weight on carbon). The organic solution was collected, and the solvent was removed under reduced pressure to give the title compound as a white solid (0.013 g, 0.015 mmol, 90%), which was further purified using RP-HPLC using a gradient of 0–55% CH₃CN in 0.1% TFA/H₂O over 45 min [α]_D²⁴ +166.11 (c 0.50, MeOH). ¹H NMR (500 MHz, CD₃OD): δ 7.41 (d, *J*=1.5 Hz, 1H), 7.27 (ddd, *J*=16.0, 8.0 and 1.0 Hz, 2H), 7.08 (d, *J*=2.0 Hz, 1H), 6.97 (dq, *J*=8.0 and 2.5 Hz, 2H), 6.75 (td, *J*=12.5 and 4.5 Hz, 2H), 5.02–5.10 (m, 3H), 4.65–4.75 (m, 3H), 4.57–4.65 (m, 3H), 4.04 (d, *J*=9.0 Hz, 1H), 3.90 (dd, *J*=12.0 and 2.0 Hz, 1H), 3.71–3.77 (m, 1H), 3.42–3.50 (m, 2H), 3.35–3.42 (m, 2H). ¹³C NMR (125 MHz, CD₃OD): 169.5, 169.4, 169.36, 169.3, 169.2, 148.1, 148.0, 147.8, 145.8, 145.5, 130.4, 118.74, 118.72, 118.4, 118.3, 118.2, 117.8, 115.4, 115.3, 114.7, 81.7, 80.6, 78.3, 74.9, 70.4, 64.43, 64.40, 64.3, 61.6, 52.2, 52.1, 52.0. HRMS (ESI): m/z [M][–] found 830.1898, calcd 830.1892 for C₃₆H₃₆N₃O₂₀.

4.6.17. (*S,R,R,S,R*)-*N,N'*-((3*S*,7*S*,11*S*)-11-(2,3-Dihydroxybenzamido)-2,6,10-trioxo-1,5,9-trioxacyclododecane-3,7-diyl)bis(2,3-dihydroxy-5-((2*S*,3*R*,4*R*,5*S*,6*R*)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)benzamide) (DGE). This compound was prepared

according to the general procedure B using Per-Bn-DGE **8** (0.030 g, 0.013 mmol, 100 mol %) and Pd(OH)₂ (0.035 g, 20% weight on carbon). The organic solution was collected, and the solvent was removed under reduced pressure to give the title compound as a white solid (0.012 g, 0.012 mmol, 92%), which was further purified with RP-HPLC using a gradient of 0–45% CH₃CN in 0.1% TFA/H₂O over 40 min [α]_D²⁴ +310.68 (c 0.40, MeOH). ¹H NMR (500 MHz, CD₃OD): δ 7.41 (dd, *J*=2.0 and 1.0 Hz, 2H), 7.29 (d, *J*=8.0 Hz, 1H), 7.07 (d, *J*=1.5 Hz, 2H), 6.90 (dd, *J*=8.0 and 1.0 Hz, 1H), 6.76 (t, *J*=8.0 Hz, 1H), 5.07 (dd, *J*=10.0 and 5.0 Hz, 3H), 4.68–4.75 (m, 3H), 4.60 (td, *J*=12.5 and 4.5 Hz, 3H), 4.05 (dd, *J*=9.5 and 3.5 Hz, 2H), 3.89 (dd, *J*=11.5 and 1.5 Hz, 2H), 3.73 (ddd, *J*=12.0, 5.5 and 2.0 Hz, 2H), 3.50–3.35 (m, 8H). ¹³C NMR (125 MHz, CD₃OD): δ 169.5, 169.4, 169.3, 169.2, 148.0, 147.88, 147.85, 147.7, 145.4, 130.34, 130.32, 118.74, 118.71, 118.4, 117.8, 117.7, 115.4, 114.7, 81.7, 81.6, 80.6, 80.5, 78.3, 74.9, 70.4, 64.4, 64.3, 61.6, 61.5, 52.2, 52.02, 52.0. HRMS (MALDI): m/z [M+Na]⁺ found 1016.2391, calcd 1016.2396 for C₄₂H₄₇N₃O₂₅Na.

4.6.18. (*S,R,R,S,R,S,R,R,S,R*)-*N,N'*-((3*S*,7*S*,11*S*)-2,6,10-Trioxo-1,5,9-trioxacyclododecane-3,7,11-triyl)tris(2,3-dihydroxy-5-((2*S*,3*R*,4*R*,5*S*,6*R*)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)benzamide) (TGE). This compound was prepared according to the general procedure B using Per-Bn-TGE **3** (0.050 g, 0.018 mmol, 100 mol %) and Pd(OH)₂ (0.040 g, 20% weight on carbon). The organic solution was collected, and the solvent was removed under reduced pressure to give the title compound as a white solid (0.019 g, 0.017 mmol, 92%), which was further purified with RP-HPLC using a gradient of 0–40% CH₃CN in 0.1% TFA/H₂O over 40 min [α]_D²⁴ +389.57 (c 0.90, DCM). ¹H NMR (500 MHz, CD₃OD): δ 7.41 (s, 3H), 7.07 (s, 3H), 5.07 (dd, *J*=8.0 and 4.0 Hz, 3H), 4.72 (dd, *J*=11.0 and 7 Hz, 3H), 4.59 (dd, *J*=11.0 and 3.5 Hz, 3H), 4.04 (d, *J*=9.0 Hz, 3H), 3.88 (dd, *J*=12.0 and 2.0 Hz, 3H), 3.73 (dd, *J*=11.5 and 5.0 Hz, 3H), 3.50–3.32 (m, 12H). ¹³C NMR (125 MHz, CD₃OD/DMSO-*d*₆): 170.8, 170.7, 149.2, 146.8, 131.7, 119.9, 119.2, 116.2, 83.0, 82.0, 79.7, 76.3, 71.8, 65.9, 63.0, 53.5. HRMS (ESI): m/z [M][–] found 1154.2954, calcd 1154.2949 for C₄₈H₅₆N₃O₃₀.

Acknowledgements

H.G. was grateful to Professors Jianhui Fang, Jiaqiang Xu, and Qiyi Pan for their generous assistance for lab setup. Doctors Luke Nelsen and Alison Campbell were thanked for proofreading the manuscript. Andrew Blanchard and Qing Zhu were acknowledged for their contribution to the preparation of **1** and **12**, respectively. Financial support was provided by the department of chemistry, the college of Natural Sciences at Shanghai University, and Shanghai Leading Academic Discipline Project (NO. S30107).

Supplementary data

Supplementary data associated with this article can be found in online version, at doi:10.1016/j.tet.2010.11.007. These data include MOL files and InChIKeys of the most important compounds described in this article.

References and notes

- (a) Sandy, M.; Butler, A. *Chem. Rev.* **2009**, *109*, 4580–4595; (b) Hoette, T. M.; Abergel, R. J.; Xu, J.; Strong, R. K.; Raymond, K. N. *J. Am. Chem. Soc.* **2008**, *130*, 17584–17592.
- For selected examples, see: (a) Abergel, R. J.; Zawadzka, A. M.; Hoette, T. M.; Raymond, K. N. *J. Am. Chem. Soc.* **2009**, *131*, 12682–12692; (b) Loomis, L. D.; Raymond, K. N. *Inorg. Chem.* **1991**, *30*, 906–911; (c) Harris, W. R.; Carrano, C. J.; Cooper, S. R.; Sofen, S. R.; Avdeef, A. A.; McArdle, J. V.; Raymond, K. N. *J. Am. Chem. Soc.* **1979**, *101*, 6097–6104.
- (a) Müller, S. I.; Valdebenito, M.; Hantke, K. *Biomaterials* **2009**, *22*, 691–695; (b) Bister, B.; Bischoff, D.; Nicholson, G. J.; Valdebenito, M.; Schneider, K.; Winkelmann, G.; Hantke, K.; Sussmuth, R. D. *Biomaterials* **2004**, *17*, 471–481; (c)

- Hantke, K.; Nicholson, G.; Rabsch, W.; Winkelmann, G. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 3677–3682.
4. Smith, K. D. *Int. J. Biochem. Cell Biol.* **2007**, *39*, 1776–1780.
5. (a) Fischbach, M. A.; Lin, H.; Liu, D. R.; Walsh, C. T. *Nat. Chem. Biol.* **2006**, *2*, 132–138; (b) Nolan, E. M.; Fischbach, M. A.; Koglin, A.; Walsh, C. T. *J. Am. Chem. Soc.* **2007**, *129*, 14336–14373; (c) Fischbach, M. A.; Lin, H.; Liu, D. R.; Walsh, C. T. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 571–576; (d) Lin, H.; Fischbach, M. A.; Liu, D. R.; Walsh, C. T. *J. Am. Chem. Soc.* **2005**, *127*, 11075–11084.
6. For selected examples, see: (a) Crouch, M.-L.; Castor, M.; Karlnessy, J. E.; Kalhorn, T.; Fang, F. C. *Mol. Microbiol.* **2008**, *67*, 971–983; (b) Caza, M.; Lépine, F.; Milot, S.; Dozois, C. M. *Infect. Immun.* **2008**, *76*, 3539–3549.
7. For selected examples of synthetic Ent analogs and their applications, see: (a) Lin, H.; Fischbach, M. A.; Gatto, G. J., Jr.; Liu, D. R.; Walsh, C. T. *J. Am. Chem. Soc.* **2006**, *128*, 9324–9325; (b) Bluhm, M. E.; Kim, S. S.; Dertz, E. A.; Raymond, K. N. *J. Am. Chem. Soc.* **2002**, *124*, 2436–2447; (c) Wang, Y.; Duran, E.; Nacionales, D.; Valencia, A.; Wostenberg, C.; Marinez, E. R. *Tetrahedron Lett.* **2008**, *49*, 6410–6412.
8. (a) Gong, H.; Gagné, M. R. *J. Am. Chem. Soc.* **2008**, *130*, 12177–12183; (b) Gong, H.; Sinisi, R.; Gagné, M. R. *J. Am. Chem. Soc.* **2007**, *129*, 1908–1909.
9. For reviews in C-glycoside synthesis, see: (a) Meo, P.; Osborn, H. M. I. *Best Synthetic Methods: Carbohydrates*; Elsevier Science Ltd.: New York, NY, 2003; pp 337–384; (b) Du, Y.; Linhardt, R. J.; Vlahov, I. R. *Tetrahedron* **1998**, *54*, 9913–9959; (c) Postema, M. H. D. *C-Glycoside Synthesis*; CRC: Boca Raton, FL, 1995.
10. For reviews in aryl-C-glycoside synthesis, see: (a) Wellington, K. W.; Benner, S. A. *Nucleosides, Nucleotides Nucleic Acids* **2006**, *25*, 1309–1333; (b) Lee, D. Y. W.; He, M. *Curr. Top. Med. Chem.* **2005**, *5*, 1333–1350; (c) Bililign, T.; Griffith, B. R.; Thorson, J. S. *Nat. Prod. Rep.* **2005**, *22*, 742–760.
11. (a) Ramirez, R. J.; Karamanukyan, L.; Ortiz, S.; Gutierrez, C. G. *Tetrahedron Lett.* **1997**, *38*, 749–752; (b) Meyer, M.; Telford, J. R.; Cohen, S. M.; White, D. J.; Xu, J.; Raymond, K. N. *J. Am. Chem. Soc.* **1997**, *119*, 10093–10103.
12. See [Supplementary data](#)
13. It was determined that deprotection of Boc groups with TFA was much less effective than HCl in THF.
14. (a) Rastetter, W. H.; Erickson, T. J.; Venuti, M. C. *J. Org. Chem.* **1981**, *46*, 3579–3590; (b) Murata, A.; Wada, T. *Bioorg. med. Chem. Lett.* **2006**, *16*, 2933–2936.
15. For an example of rapid O→N acyl shift, see: Yoshiya, T.; Taniguchi, A.; Sohma, Y.; Fukao, F.; Nakamura, S.; Abe, N.; Ito, N.; Skwarczynski, M.; Kimura, T.; Hayashi, Y.; Kiso, Y. *Org. Biomol. Chem.* **2007**, *5*, 1720–1730.
16. An inseparable mixture was obtained in which trace amount of **18** was determined by NMR.
17. For methods used for subduing O to N-acyl migration in the synthesis of L-156602, actinomycin and the azinotricin family, involving cyclic ester bond-linked amino acid cores, see: (a) Hale, K. J.; Manaviar, S.; George, J. H.; Walters, M. A.; Dalby, S. M. *Org. Lett.* **2009**, *11*, 733–736; (b) Meienhofer, J. J. *Am. Chem. Soc.* **1970**, *92*, 3771–3777; (c) Kopka, I. E. *Tetrahedron Lett.* **1990**, *31*, 4711–4714.